$DABUR

Dabur India fell more than 4 percent on Monday despite the FMCG company stating that it is working closely with the US Food and Drug Administration (USFDA) to address observations made during an inspection of its Silvassa manufacturing facility. In a regulatory filing, Dabur clarified that the observations pertain only to a limited section of the Silvassa plant in Dadra and Nagar Haveli and that the facility contributes only a negligible portion of the company’s overall revenue. The company said it has developed a corrective and preventive action (CAPA) plan to resolve the issues highlighted by the USFDA. The plan has already been submitted to the regulator, and Dabur is providing regular updates on its implementation. According to a Reuters report, the USFDA identified concerns related to data integrity, manufacturing practices, and maintenance procedures during an inspection conducted at the facility in January this year. The inspection report noted that certain areas of the plant could be vulnerable to microbiological contamination. The report further alleged that some critical manufacturing records had been falsified to conceal the use of equipment designated for specific products in the production of multiple other products. Dabur said it is actively engaging with the USFDA to address all observations and ensure compliance with regulatory standards.